Dermal fibroblasts derived from fetal and postnatal humans exhibit distinct responses to insulin like growth factors by Rolfe, Kerstin J et al.
BioMed  Central
Page 1 of 13
(page number not for citation purposes)
BMC Developmental Biology
Open Access Research article
Dermal fibroblasts derived from fetal and postnatal humans exhibit 
distinct responses to insulin like growth factors
Kerstin J Rolfe*1, Alison D Cambrey1, Janette Richardson1, Laurie M Irvine2, 
Adriaan O Grobbelaar3 and Claire Linge1
Address: 1RAFT Institute of Plastic Surgery, Leopold Muller Building, Mount Vernon Hospital, Northwood Middlesex. UK, 2Department of 
Obstetrics and Gynaecology, Watford General Hospital, Vicarage Road, Watford. UK and 3Department of Plastic and Reconstructive Surgery, The 
Royal Free Hospital, Pond Street, Hampstead, London. UK
Email: Kerstin J Rolfe* - rolfek@raft.ac.uk; Alison D Cambrey - admin@raft.ac.uk; Janette Richardson - richardsonj@raft.ac.uk; 
Laurie M Irvine - laurie.irvine@whht.nhs.uk; Adriaan O Grobbelaar - rolfek@raft.ac.uk; Claire Linge - lingec@raft.ac.uk
* Corresponding author    
Abstract
Background: It has been well established that human fetuses will heal cutaneous wounds with
perfect regeneration. Insulin-like growth factors are pro-fibrotic fibroblast mitogens that have
important roles in both adult wound healing and during development, although their relative
contribution towards fetal wound healing is currently unknown. We have compared responses to
IGF-I and -II in human dermal fibroblast strains derived from early gestational age fetal (<14 weeks)
and developmentally mature postnatal skin to identify any differences that might relate to their
respective wound healing responses of regeneration or fibrosis.
Results: We have established that the mitogenic response of fetal cells to both IGF-I and -II is
much lower than that seen in postnatal dermal fibroblasts. Further, unlike postnatal cells, fetal cells
fail to synthesise collagen in response to IGF-I, whereas they do increase synthesis in response to
IGF-II. This apparent developmentally regulated difference in response to these related growth
factors is also reflected in changes in the tyrosine phosphorylation pattern of a number of proteins.
Postnatal cells exhibit a significant increase in phosphorylation of ERK 1 (p44) in response to IGF-
I and conversely the p46 isoform of Shc on IGF-II stimulation. Fetal cells however only show a
significant increase in an unidentified 100 kDa tyrosine-phosphorylated protein on stimulation with
IGF-II.
Conclusion: Dermal fibroblasts exhibit different responses to the two forms of IGF depending on
their developmental maturity. This may relate to the developmental transition in cutaneous wound
healing from regeneration to fibrosis.
Background
It has been known for several decades that human fetuses
will heal cutaneous wounds without scarring [1]. Row-
latt's work documented that early human fetuses heal
their cutaneous wounds by mesenchymal proliferation
resulting in perfect regeneration [1]. Furthermore,
although the extracellular matrix (ECM) deposited during
fetal wound regeneration is the same composition as that
identified in postnatal and adult wound healing they
exhibit a distinct difference in the temporal and spatial
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distribution of each component. For example, the deposi-
tion of collagen in fetal repair is indistinguishable from
that of the surrounding uninjured tissue whereas in the
postnatal human, collagen deposition during wound
healing is disorganised [2]. It has therefore been proposed
by a number of groups that fetal fibroblasts are the key
repair 'effector' cells because it is believed that they dictate
collagen deposition, the main component of the dermal
ECM [3].
IGF-I is believed to play a role in adult wound healing
through its action on fibroblasts and others have shown
that the expression of IGF-I and -II increases substantially
between days 1–21 post wounding [4,5]. IGF-I plays an
important role in cell growth both in vitro and in vivo [4];
and is known to stimulate fibroblast mitogenesis and
ECM synthesis[6]. IGF-I's biological actions are mediated
by its receptor, a tyrosine kinase, IGF-IR [7]. Binding of
IGF-I to its receptor (IGF-IR) results in receptor autophos-
phorylation followed by phosphorylation of a number of
adaptor signalling proteins such as Shc [7]. Studies have
shown that the phosphorylation of Shc followed by
MAPKs causes mitogenesis and that IGF-I increases colla-
gen type I mRNA also via the MAPK pathway [8,9].
Treatment of wounds with IGF-I has been shown to accel-
erate wound healing by the stimulation of fibroblast col-
lagen synthesis, in addition to its mitogenic effect on both
keratinocytes and fibroblasts [10,4]. However IGF-I has
also been implicated in a range of fibrotic conditions e.g.
keloids, hypertrophic scars, Crohn's disease, fibrotic lung
disease and glomerular disease [11-14].
Although both IGF-I and IGF-II are expressed in the
embryo, IGF-II is thought to have a predominant role
early on in development [15]. IGF-II is a member of a
small family of genes that have been shown to be subject
to genomic imprinting [16,17]. An imprinted gene is
expressed primarily from one specific parental allele and
such genes have been shown to exert important effects,
primarily on fetal development. IGF-II acts through the
same receptor as IGF-I, the tyrosine kinase IGF type I
receptor, but also binds both the insulin receptor and the
IGF type II receptor which is thought to be responsible for
IGF-II degradation [18]. DeChiara et al, showed that IGF-
II is required for normal fetal growth, as IGF-II null mice
were 60% smaller than their wild type littermates [19,20].
However, these growth deficient animals were otherwise
apparently healthy and fertile, so IGF-II is not essential for
development or survival. Conversely experiments on IGF-
I homozygote knockout mice (Igf I-/-) have shown that
animals are not only reduced in size but display severe
muscle dystrophy and most (>95%) died at birth [21].
Clearly therefore both IGF proteins play distinct roles dur-
ing fetal development and growth. Nevertheless the rela-
tive contribution of each IGF during fetal wound healing
is currently unknown.
The aim of this study was to determine if early gestational
age human fetal dermal fibroblasts (FDF) respond in the
same manner as their developmentally mature counter-
parts (MDF) to the addition of exogenous IGF-I and IGF-
II with regard to proliferation, collagen production and
finally intracellular signalling. Any differences detected
may contribute towards the ability of fetal but not devel-
opmentally mature fibroblasts to regenerate the dermis
rather than form scar tissue. Our data demonstrates clear
differences in cellular responses between the two cell
types, with FDF demonstrating minimal mitogenic
response to either form of IGF and failing to synthesise
collagen in response to IGF-I but not IGF-II. Distinct pat-
terns in the phosphorylation of intracellular proteins in
response to IGF stimulus were also identified for FDF and
MDF. The contrasting responses of dermal fibroblasts
from different developmental stages to these important
cytokines may well relate to their dissimilar wound heal-
ing responses of either perfect regeneration of dermal
architecture or crude filling of the tissue deficit by scar tis-
sue formation.
Results
Fibroblast proliferation
A comparison of the proliferative responses to IGF-I and
IGF-II by FDF and MDF are shown in Figure 1A and 1B
respectively. Identical results were obtained using the
WST-1 assay (Figure 1) and the crystal violet proliferation
assay (data not shown). MDF demonstrated a clear dose
dependent response to IGF-I, with significant increases in
cell number above that observed by the untreated control
at all concentrations tested (p < 0.05; Figure 1A). The
increase in MDF cell number reached a maximum of over
four times that of the untreated control at the highest con-
centration tested (300 ng/ml). In contrast FDF showed a
less profound response with a much lower maximal
response of twice that of the untreated control, which was
reached at a lower concentration of IGF-I at 25 ng/ml,
although only became statistically significant at 100 and
300 ng/ml IGF-I (p = 0.0005 and 0.0013 respectively).
This response was significantly lower than that exhibited
by the MDF cell strains at the two highest IGF-I concentra-
tions tested (100 ng/ml, p = 0.0366 and 300 ng/ml, p =
0.0169).
The proliferative response to IGF-II was almost identical
to that of IGF-I, showing an increase in proliferation
induced for both cell types although again to a lesser
extent by FDF compared to MDF cell strains (Figure 1B).
FDF showed a significant increase (p < 0.05) throughout
the concentration range used compared to untreated cells,
whereas although MDF exhibited a greater responseBMC Developmental Biology 2007, 7:124 http://www.biomedcentral.com/1471-213X/7/124
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throughout the concentration range this was only signifi-
cantly different from their untreated controls at 100 ng/ml
(p = 0.0500) and 300 ng/ml (p = 0.0350) due to high var-
iability at lower concentrations. Nevertheless the maximal
response seen with MDF cell strains was again over four
times greater than untreated controls, whereas that seen
for FDF strains was significantly lower at 100 (p = 0.0320)
and 300 ng/ml (p = 0.0039) being only twice that seen in
the untreated FDF control.
Collagen synthesis
Modulation of collagen synthesis by IGF-I and II were esti-
mated in vitro and the responses between FDF and MDF
cell strains compared. IGF-I elicited a dose dependent
increase in collagen synthesis by MDF (Figure 2A). Colla-
gen synthesis became maximal at concentrations of 50 ng/
ml and over, a 39% (p < 0.05) increase above that elicited
by untreated control cells. By contrast, non-collagen pro-
tein synthesis did not significantly alter in response to
IGF-I, regardless of concentration assessed (Figure 2B). A
comparison of the effect of IGF-I on the levels of collagen
synthesised as a proportion of total protein produced over
the exposure period is shown in Figure 2C. This demon-
Collagen production in response to IGF-I Figure 2
Collagen production in response to IGF-I. Radio-labelled proline 
uptake assay demonstrating modulation of protein synthesis by IGF-I. 
Panel A and B depict IGF-I elicited changes in collagen and non-collagen 
synthesis respectively, by FDF (n = 3, open squares) and MDF (n = 3, 
closed diamonds). All data is represented as cpm/105 cells (mean ± sem). 
Panel C illustrates changes in relative collagen synthesis between MDF and 
FDF in response to IGF-I; data represented as % (mean ± sem). * p = < 
0.05. MDF cell strains demonstrated significantly higher collagen synthesis 
than untreated controls at 50 and 100 ng/ml of IGF-I (*p = 0.034 and 0.047 
respectively); and significantly higher %RCS than untreated controls at 10, 
50 and 100 ng/ml of IGF-I (*p = 0.047, 0.021 and 0.028 respectively). In 
contrast FDF cell strains showed no significant effect of IGF-I treatment on 
either collagen or protein synthesis over the entire titration range.
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Proliferation response of dermal fibroblasts to IGF-I and IGF- II Figure 1
Proliferation response of dermal fibroblasts to IGF-I and IGF-II. 
A: The mean proliferation curve in response to IGF-I at 72 hrs for both 
FDF (open squares; n = 3) and MDF (closed diamonds; n = 3) in 0.4% FCS-
containing medium. Error bars = SEM. (*p = < 0.05; **p = < 0.005). FDF 
only showed statistical difference at 100 and 300 ng/ml. MDF showed a 
statistical increase in proliferation at 25 ng/ml, 50 ng/ml, 100 ng/ml and 300 
ng/ml compared to untreated controls. B: The mean proliferation curve in 
response to IGF-II at 72 h for both FDF (open squares; n = 3) and MDF 
(closed diamonds; n = 3) in 0.4% FCS-containing medium. Error bars = 
SEM. (*p = < 0.05). FDF showed a statistical increase throughout the con-
centration range compared to untreated controls. MDF showed a statisti-
cal significance from the untreated control at 100 and 300 ng/ml.
0
50
100
150
200
250
300
350
400
450
500
0 50 100 150 200 250 300 350
IGF-I (ng/ml)
%
 
c
h
a
n
g
e
 
f
r
o
m
 
t
0
 
0
50
100
150
200
250
300
350
400
450
0 50 100 150 200 250 300 350
IGF-II (ng/ml)
%
 
c
h
a
n
g
e
 
f
r
o
m
 
t
0
A 
B 
*
*
* * * *
* 
**
* 
*
**
* BMC Developmental Biology 2007, 7:124 http://www.biomedcentral.com/1471-213X/7/124
Page 4 of 13
(page number not for citation purposes)
strates that IGF-1 (10 – 100 ng/ml) significantly and selec-
tively increases collagen synthesis; above any effects on
total protein production compared with untreated control
cells (p < 0.05). In contrast, FDF did not exhibit any sig-
nificant response to IGF-I, with regard to either collagen
or non-collagen synthesis. Indeed ANOVA analysis of the
relative collagen synthesis data determined a statistically
significant difference (p = 0.016) in the response of FDF
and MDF.
Figure 3 demonstrates the contrasting results obtained
with IGF-II, with the only significant increase in collagen
synthesis (36% over that of the untreated control) being
exhibited by fetal cells at 100 ng/ml (Figure 3A). There
was no significant effect on general protein synthesis by
either cell type and IGF-II had no significant effect on
either total or relative collagen synthesis of MDF over the
entire concentration range tested. ANOVA analysis of col-
lagen synthesis as a proportion of total protein synthesis
demonstrated that fetal cells show a significantly different
relative collagen synthesis over that of MDF (p = 0.010,
Figure 3C), with FDF being significantly higher than MDF
at 50 ng/ml of IGF-II (p = 0.016).
Quantification of IGF-I Receptor (IGF-1R)
Protein lysates from quiescent cells treated with serum
free media alone were analysed for expression of IGF-IR
using SDS-PAGE and Western blotting using a specific
antibody. A typical Western blot for both IGF-IR and load-
ing control together with the graph showing the densito-
metric analysis of band density after correction for equal
loading is shown in Figure 4A–B. Statistical analysis failed
to detect any significant difference between the IGF-IR
expression of FDF cell strains and MDF (n = 3 each). Flu-
orescence activated cell sorter (FACS) analysis was also
performed (data not shown) on FDF and MDF cell strains
(n = 2 of each) to quantify the relative levels of cell surface
IGF-IR, and demonstrated no significant difference
between the two different cell sources.
Intracellular signalling
Tyrosine phosphorylated proteins
Protein lysates from quiescent cells treated with serum
free media alone (unstimulated control) or with the addi-
tion of either exogenous IGF-I or IGF-II were analysed by
Western blot using an antibody specific for tyrosine phos-
phorylated proteins. Western blots were assessed by den-
sitometry after ensuring that each sample had equal
loading by the use of the MemCode Reversible™ protein
stain (Figure 5B). A number of tyrosine phosphorylated
protein bands were clearly identified in both untreated
FDF and untreated MDF lysates and IGF-I or IGF-II stimu-
lated groups (Figure 5A and 6A respectively). The pattern
(number and position) of tyrosine phosphorylated bands
was the same for both FDF and MDF cells strains and did
not change on stimulation. Although the density of all
bands appeared higher in unstimulated FDF compared to
MDF, this only reached significance for the 66 kDa band
(Figure 5C; p = 0.024).
Collagen production in response to IGF-II Figure 3
Collagen production in response to IGF-II. Radio-labelled proline 
uptake assay demonstrating modulation of protein synthesis by IGF-II. 
Panel A and B depict IGF-II elicited changes in collagen and non-collagen 
synthesis respectively, by FDF (n = 3, open squares) and MDF (n = 3, 
closed diamonds). All data is represented as cpm/105 cells (mean ± sem). 
Panel C illustrates changes in relative collagen synthesis between MDF and 
FDF in response to IGF-II; data represented as % (mean ± sem). * p = < 
0.05. Collagen synthesis was significantly higher for FDF over untreated 
control at 100 ng/ml IGF-II. There was no significant change in non-colla-
gen synthesis for either cell type. Student t-tests demonstrated that the 
%RCS produced by FDF with 50 ng/ml IGF-II was significantly higher than 
that produced by PDF (*p = 0.016). ANOVA analysis showed that both 
collagen count data and % RCS data from FDF are highly significantly differ-
ent (p = 0.003 and 0.010 respectively) from PDF cell strain data.
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The density of all the tyrosine phosphorylated protein
bands appeared slightly higher in MDF cell strains after
stimulation with IGF-I, but were mainly unchanged or
lower for FDF cell strains, however none of these differ-
ences reached statistical significance (Figure 5C). The only
exception to these apparent trends was a band at 50 kDa
in FDF cell strains, which increased on IGF-I stimulation,
but again this increase failed to reach statistical signifi-
cance. Despite the similar tendency of this band to
increase in density on IGF-I stimulation in MDF and FDF
strains alike, that of MDF cells was significantly lower
than that of fetal cells (p = 0.028).
Both FDF and MDF demonstrated a trend toward
increased density of most tyrosine phosphorylated pro-
tein bands after IGF-II stimulation (Figure 6). This
increase in density on stimulation was statistically signifi-
cant (p = 0.029) for the 100 kDa band seen in FDF lysates,
but failed to reach statistical significance for all bands
detected in the MDF strain lysates, The increased tyrosine
phosphorylation of this 100 kDa band in FDF strains was
also significantly higher than that induced in MDF (p =
0.049). An exception to this overall increase in band den-
sity on stimulation was a tyrosine-phosphorylated band at
50 kDa in FDF cell strains, which was significantly
reduced (p = 0.048).
Shc
Protein lysates were immunoprecipitated, with an anti-
Shc antibody and the precipitate electrophoresed and ana-
Tyrosine phosphorylated proteins after stimulation with IGF- I Figure 5
Tyrosine phosphorylated proteins after stimulation with IGF-I. A: 
Protein lysates from cells treated with IGF-I for 20 mins were analysed by 
Western blot using a specific antibody against tyrosine phosphorylated 
proteins. B: To ensure equal loading used the MemCode Reversible™ 
protein stain (Pierce Biotechnology). C: The graph represents the change 
in tyrosine phosphorylation after ensuring for equal loading. The graph 
represents the results for FDF (n = 5; closed bar un-stimulated, diamonds 
represents stimulated cells) and MDF (n = 5 hash bar represents un-stimu-
lated and the closed bar stimulated). Error bars = SEM. A statistical 
increase was shown in FDF following stimulation with IGF-I compared to 
MDF at 50 kDa (*p = 0.028); a further statistical difference was shown 
with an increase of a band at 66 kDa in unstimulated FDF cells compared 
to unstimulated MDF (**p = 0.024). Two way ANOVA showed a statistical 
significant (p = 0.007) difference in the mean values among the different 
cell type greater than would be expected by chance allowing for the differ-
ence in treatment.
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IGF-IR in dermal fibroblasts Figure 4
IGF-IR in dermal fibroblasts. A: Protein lysates from quiescent cells 
were analysed by Western blot using a specific antibody against IGF-IR. B: 
To ensure equal loading β-actin was also used. C: The graph represents 
the change in IGF-IR between MDF and FDF cell strains (n = 3 for each). 
Error bars = SEM. No statistical significant difference was demonstrated 
between the cell types.BMC Developmental Biology 2007, 7:124 http://www.biomedcentral.com/1471-213X/7/124
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lysed by Western blotting with an anti-tyrosine phospho-
rylated antibody. Three bands were identified, which
corresponded to the three isoforms of Shc, 46 kDa, 52
kDa and 66 kDa (Figure 7A).
The apparently higher levels of tyrosine phosphorylated
52 kDa Shc exhibited by unstimulated FDF strains com-
pared to both IGF-I stimulated FDF cells and MDF cells
irrespective of stimulation did not reach statistical signifi-
cance. The other isoforms clearly showed no difference
between cell strains or between IGF-I treated and
untreated control. On combining data for the similar act-
ing Shc isoforms (p46 and p52), the elevated expression
of p46/p52 seen for untreated FDF, over both untreated
MDF and IGF-I treated FDF still failed to reach statistical
significance.
Protein lysates from cells stimulated with exogenous IGF-
II were also immunoprecipitated with an anti-Shc anti-
body and analysed by Western blotting as described pre-
Tyrosine phosphorylated Shc after stimulation with IGF-I Figure 7
Tyrosine phosphorylated Shc after stimulation with IGF-I. A: Pro-
tein lysates from cells treated with IGF-I for 20 mins were analysed by 
Western blot. A: Shows a representative western blot analysis for total 
Shc. Protein lysates were immunoprecipiated with an anti-Shc antibody as 
described in the materials and methods and the precipitate was run on a 
western blot and stained with the antibody p-Tyr and a representative 
western is shown in B. B: A graph representing the densitometry, after 
correcting for total-Shc. Bars show average for n = 5 FDF and n = 5 MDF 
and SEM (closed bar 46 kDa, open bar 52 kDa, and hashed bar 66 kDa). 
No statistical difference was demonstrated for any group.
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Tyrosine phosphorylated proteins after stimulation with IGF- II Figure 6
Tyrosine phosphorylated proteins after stimulation with IGF-II. 
A: Representative Western blot. Protein lysates from cells treated with 
IGF-II for 20 mins were analysed by Western blot using a specific antibody 
against tyrosine phosphorylated proteins. B: To ensure equal loading used 
the MemCode Reversible™ protein stain (Pierce Biotechnology) C: The 
graph represents the mean change in tyrosine phosphorylation after 
ensuring for equal loading following stimulation with IGF-II for FDF (n = 5 
open bar un-stimulated; lined bar represents stimulated lysates) and MDF 
(n = 5 closed bar represents un-stimulated lysates; thick lines represents 
stimulated lysates). Error bars = SEM. A statistical decrease in FDF (p = 
0.048) was identified for a band at 50 kDa following stimulation with IGF-
II. FDF showed a statistical increase when comparing un-stimulated cells 
with stimulated cells at 100 kDa (p = 0.029) and a further statistical 
increase was demonstrated between FDF and MDF when cells had been 
stimulated with IGF-II at for a band at 100 kDa (p = 0.049).
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viously. FDF and MDF showed different patterns of Shc
phosphorylation (Figure 8), with MDF showing a signifi-
cant increase in the phosphorylated form of p46 with
stimulation (p = 0.03) whereas FDF did not. Indeed there
was significantly lower phosphorylated p46 in stimulated
FDF compared to stimulated MDF (p = 0.004). Unstimu-
lated FDF cells in this experiment also showed the same
elevated p52 as that demonstrated in the IGF-I experi-
ment, though again this did not reach statistical signifi-
cance between either cell strain types or treatments.
Combining data for the similar acting p46 and p52 iso-
forms, there was again no statistical significance between
cell strains or between untreated and IGF-II treated sam-
ples.
p-ERK
Protein lysates were electrophoresed and analysed by
Western blotting which was probed with an anti-p-ERK
antibody. MDF significantly increased phosphorylated
p44 on IGF-I stimulation (p = 0.04; Figure 9). A similar
trend was demonstrated for phosphorylated p42, however
this just failed to reach significance (p = 0.07). In contrast,
the pattern of phosphorylation of both ERK isoforms in
FDF did not alter on stimulation with IGF-I. Indeed, the
amount of phosphorylated p42 detected in IGF-I-treated
FDF cells was shown to be significantly lower than that
seen in stimulated MDF cells (p = 0.04).
Stimulation with IGF-II showed no change in ERK phos-
phorylation in MDF following stimulation whereas FDF
showed a fall in the phosphorylation of ERK with stimu-
lation though this did not reach statistical significance
(data not shown). The level of phosphorylated p44 in
MDF stimulated with IGF-II was higher compared to stim-
ulated FDF though this failed to reach statistical signifi-
cance (p = 0.061).
Discussion
The biological actions of the IGFs are well defined and
include substantial effects on growth, differentiation or
Phosphorylated MAPK in response to IGF-I Figure 9
Phosphorylated MAPK in response to IGF-I. Protein lysates from 
cells treated with exogenous IGF-I were analysed by Western blot analysis 
using a specific anti MAPK (Promega). A: shows a representative Western 
blot. B: shows a graph representing n = FDF, n = MDF with error bars 
SEM. A statistical significant increase was demonstrated for p44 in the 
MDF control (untreated group) and the MDF treated group (*p = 0.04). A 
trend towards a significant increase was also demonstrated between MDF 
control and MDF treated for p42 (p = 0.07). FDF showed no significant 
increase. A statistical significant difference was identified between stimu-
lated FDF and stimulated MDF for p42.
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Tyrosine phosphorylated Shc after stimulation with IGF-II Figure 8
Tyrosine phosphorylated Shc after stimulation with IGF-II. Pro-
tein lysates from cells treated with IGF-II for 20 mins were analysed by 
Western blot. A: Shows a representative western blot analysis for total 
Shc. Protein lysates were immunoprecipiated with an anti-Shc antibody as 
described in the materials and methods and the precipitate was run on a 
Western blot and stained with the antibody p-Tyr and a representative 
Western blot is shown in A. B: shows the graph plotting the densometry, 
after correcting for total Shc. A statistical significant difference was dem-
onstrated for p46 with MDF showing a significant increase after treatment 
(*p = 0.03) and the MDF treated group was statistically greater than the 
FDF treated group (**p = 0.004). n = 5 FDF and n = 5 MDF (closed bar 46 
kDa, open bar 52 kDa, and hashed bar 66 kDa). Error bars = SEM.
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apoptosis in a number of cell types, including fibroblasts,
and myofibroblasts [22-28]. Both forms of IGF are sub-
stantially up regulated during adult wound healing and
IGF-I at least is thought to play a prominent role via direct
effects on dermal fibroblasts [4,5,10]. Given the presence
of these cytokines throughout cutaneous wound healing
and their implication in fibrosis of other tissues, we have
compared their effects on dermal fibroblasts derived from
two developmentally distinct sources that differ in their
predisposition towards cutaneous scarring [11-14]: early
gestational age human fetuses (where scar-free wound
healing is achieved) and developmentally mature tissue
(where dermal wound healing inevitably results in scar
formation). Our study has shown that dermal fibroblasts
derived from these different sources (fetal – FDF and
mature – MDF) differ in the extent of their proliferative
response to both forms of IGF (-I and -II). Both IGF-I and
-II significantly induce the proliferation of MDF (after 72
hrs up to four times that of untreated cells), whereas FDF
showed a significantly lower proliferative response reach-
ing a maximum of only double that of the untreated con-
trol. These results suggest that human dermal fibroblasts
derived from early gestational fetuses exhibit a lower
response to the mitogenic (and therefore potentially
profibrotic) properties of these important wound healing
cytokines. As far as the authors are aware this is the first
publication that shows the effects of these IGFs on dermal
fibroblasts derived from a non-scarring phenotype (early
gestational age human fetus) and a scarring phenotype
(mature). Other studies published comparing the effects
of IGFs on "fetal" versus adult fibroblasts appear to con-
tradict our findings, however these studies used more
developmentally mature tissue sources (late gestational
age fetus or newborn respectively) rather than the non-
scarring early gestational age fetal cells used here [29,30].
Interestingly a similar reduction in proliferative response
has also been reported after stimulation with TGF-β1, by
early gestational age (14d) murine dermal fibroblasts
compared to later gestational age samples [31].
IGF-I has also been shown to stimulate collagen produc-
tion in a number of developmentally mature tissues and
cells including fibroblasts and myofibroblasts [7,32-36].
In agreement, our study has demonstrated that MDF are
stimulated to synthesise collagen, both total and relative
to total protein synthesis, in response to IGF-I. In contrast
however, FDF cells failed to show any increase collagen
synthesis in response to IGF-I. A similar tendency of devel-
opmentally immature cells and tissue exhibiting reduced
collagen synthesis has been suggested in other experimen-
tal systems, both in vivo and in vitro [37,38] ; the latter
being reported in response to stimulation with exogenous
TGF-β1 [31,39]. Indeed morphometric studies using in
situ hybridization of rabbit tissue suggest that although
collagen expression does increase on wounding in the
early fetus, that this is simply through an increase in cell
number within the wound site [40]. Adult wounds, how-
ever, increase collagen synthesis by both fibroblast migra-
tion and an induction of increased collagen expression by
individual cells.
Collagen synthesis (both total and relative) resulting from
stimulation with IGF-II was less clear-cut, but converse to
the IGF-I results appeared significantly induced in FDF
cells, with MDF cells exhibiting no significant response
over the entire titration range of this cytokine. Although
Grotendorst et al also established that IGF-II failed to
stimulate collagen synthesis in developmentally mature
cells (rat kidney fibroblasts), this absence of response may
also be tissue specific since Murphy et al demonstrated
that IGF-II but not IGF-I increased collagen synthesis in
healing adult rabbit tendons [41,42].
Interestingly our results suggest a potential developmen-
tal switch in the response of dermal fibroblasts to these
growth factors that is mirrored by known changes in their
relative expression during embryonic development, where
circulating levels of IGF-I are reported to be low in the
fetus and increase throughout gestation, whereas IGF-II
predominates in fetuses [43-45].
The IGF-I receptor, IGF-IR, is a tyrosine kinase that medi-
ates IGF-I's biological actions, any changes of which
would affect cellular responses [7]. However, Western
blotting of total protein levels of IGF-IR and FACS analysis
of cell surface levels of IGF-IR demonstrate identical
expression by both MDF and FDF.
Cell regulation and cell responses to growth factors such
as the IGFs are relayed by a number of pathways involving
intracellular signalling proteins, often involving alteration
of the phosphorylation state of tyrosine, serine, or threo-
nine residues on a number of intracellular signalling pro-
teins [46-48]. Furthermore, a close correlation exists
between increased tyrosine phosphorylation and
increased activity of a number of receptor tyrosine kinases
such as the IGF-I receptor. Work to date on the role of
tyrosine phosphorylation in fetal regeneration has solely
used animal models e.g. rat, where five tyrosine phospho-
rylated protein bands were identified in quiescent fetal
dermal fibroblasts (170, 130, 66, 52, 46 kDa) whereas
postnatal specimens showed only one band (190 kDa)
[38]. However, further work by Chin et al on human der-
mal fibroblasts from developmentally mature tissue dem-
onstrated the same pattern of five bands as that seen in
fetal rat cells [49]. In addition, our work using a commer-
cially available antibody and cells that had been quiescent
for 72 hrs demonstrated comparable patterns of multiple
phosphorylated protein bands ranging from 37–250 kDa
in both FDF and MDF in the absences of stimulation withBMC Developmental Biology 2007, 7:124 http://www.biomedcentral.com/1471-213X/7/124
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either of the IGFs. On stimulation with IGF-I we saw no
significant change in either the band pattern or band den-
sities in either MDF or FDF cell preparations. Similarly,
Chin et al also found no enhancement of the tyrosine
phosphorylation pattern for the five bands identified in
quiescent dermal fibroblasts on stimulation with serum
[49]. On stimulation with IGF-II we did not detect any
change in banding pattern or density in MDF, however
FDF showed a statistically significant increase in the den-
sity of a 100 kDa band along with a slight but significant
decrease in the density of a 50 kDa band.
We went on to examine specific signalling proteins known
to be activated by IGF's and to be required to elicit either
their proliferative or collagen synthesis response [8,9].
The adaptor protein Shc is expressed as three known tran-
scripts with differing effects on function; Shc p52 and p46
are found in every cell type with an invariant reciprocal
relationship, whereas p66 expression varies between cell
types and is sometimes absent [50]. Shc isoforms are tyro-
sine phosphorylated after activation by a large number of
tyrosine kinase receptors e.g. that of insulin, IGFs, epider-
mal growth factor, platelet derived growth factor and
fibroblast growth factor [51,52]. Activated p46/52 iso-
forms transmit signals to other signalling proteins (e.g.
Ras) and have been implicated in the cytoplasmic propa-
gation of mitogenic signals in a number of cell types
including fibroblasts[53]. It remains unclear if p52 and
p46 have functional differences, whereas p66 is distinct
being part of the complex inhibitory-stimulatory network
that converges on growth factor regulated genes, e.g. fos
[54]. The relative positive/negative signal balance of the
three Shc isoforms within different source cells could
determine differential cellular responses to IGFs.
Surprisingly neither MDF nor FDF exhibited any statisti-
cally significant differences in the phosphorylation of all
three Shc isoforms following stimulation with IGF-I. Per-
haps of note is the observed trend of higher phosphoryla-
tion of the p52 form of Shc in FDF compared to MDF,
which appeared to be reduced on treatment with both
IGF-I and -II. Nevertheless, although these differences
were reproducible, the high variability demonstrated
between individual strains meant that they failed to reach
statistical significance. Stimulation of MDF with IGF-II
gave a significant increase in the phosphorylated form of
the Shc isoform p46, which was also significantly greater
than that seen in stimulated FDF, whereas the other two
isoforms did not significantly change. FDF showed no sig-
nificant change in any Shc isoform with stimulation of
exogenous IGF-II. The pattern of phosphorylation of Shc
isoforms does not correspond with the pattern of the 50
kD band seen in the phosphorylated tyrosine Western
blots.
Another signalling event associated with IGF-R1 function
is the activation of MAP kinase (ERK1 and ERK2) and sub-
sequent translocation into the nucleus, where it mediates
the phosphorylation of specific transcription factors, and
progression through the cell cycle [55-59]. In addition,
MAP kinase activity has been shown to be required for the
IGF-I-induced increased expression of collagen α1 (I) in
rat intestinal epithelial cells[9]. Our data has shown that
on stimulation with IGF-I quiescent MDF show an
increase in the phosphorylation of the ERKs, which was
statistically significant for p44 (ERK1). Whereas FDF cell
strains showed no change in phosphorylation pattern,
which is consistent with the reduced mitogenic response
and lack of induction of collagen synthesis seen on stim-
ulation with IGF-I. Neither FDF nor MDF showed any sig-
nificant increase in phosphorylation of ERKs after
induction with exogenous IGF-II. Others, studying differ-
ent cell types have suggested that IGF-II can activate ERK
in keratinocytes, the C2C12 cell line and the extravillous
trophoblast [60-62]. Work is on-going to assess the phos-
phorylation of ERK in response to IGF-II over a longer and
more comprehensive time course. The differing outcome
between IGF-I and IGF-II in the tyrosine phosphorylation
of proteins in FDFs compared to MDF may well be indic-
ative of a developmentally related change in response to
these growth factors.
In summary human fetal dermal fibroblasts appear to
respond differentially to the two IGFs and in an appar-
ently converse manner to that of their developmentally
mature counterparts. FDF exhibit a significantly lower
mitogenic response to both IGF-I and -II than that seen
with MDF, and furthermore unlike MDF cell strains,
clearly fail to synthesise collagen in response to IGF-I. In
contrast to MDF cell strains, fetal cells do appear to dem-
onstrate a slight induction (~30% of unstimulated levels)
of collagen synthesis in response to IGF-II. FDFs do not
appear to increase the tyrosine phosphorylation of a
number of proteins including Shc and ERKs in response to
IGF-I over the time course used. However, FDF do appear
to respond to IGF-II by significantly increasing the density
of an as yet unidentified 100 kD tyrosine-phosphorylated
protein and reducing the density of a 50 kD tyrosine-
phosphorylated protein, though again neither Shc nor
ERK showed any increase in activation with treatment. In
contrast MDF cell strains exhibited no significant differ-
ence with stimulation of either form of IGF in the general
amount of tyrosine phosphorylated proteins, although
significantly increased phosphorylation of the p46 form
of Shc after IGF-II stimulation and in the p44 form of ERK
after IGF-I stimulation. Work is ongoing to further study
the signalling pathways involved in the response of FDF to
IGF-I and -II. It may be possible in future to switch off the
specific response of postnatal cells to IGF-I, thus making
their behaviour more like that seen with fetal dermalBMC Developmental Biology 2007, 7:124 http://www.biomedcentral.com/1471-213X/7/124
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fibroblasts. Manipulation of cell behaviour from postna-
tal to fetal with regard to these cytokines may result in
improvement of scarring.
Conclusion
Dermal fibroblasts exhibit different responses to the two
forms of IGF depending on their developmental maturity.
This may relate to the developmental transition in cutane-
ous wound healing from regeneration to fibrosis.
Methods
Reagents
Recombinant growth factors IGF-I, IGF-II from R&D sys-
tems (UK). Antibodies p-Tyr (PY99), Shc (PG-797), IGF-
IR (Sc 463, Sc 462 Santa Cruz, California, USA), Anti-
Active®  MAPK (Promega, Southampton, UK), β-Actin
(Abcam, Cambridge UK). Nitrocellulose membranes were
purchased from Amersham Life Technologies (Bucks,
UK). Normal anti-rabbit and anti-mouse conjugated per-
oxidase immunoglobulins were purchased from Dako
(Ely, Cambridgeshire, UK). WST- 1 (Roche, Diagnostics
Ltd, Welwyn Garden City, Herts UK). Memcode reversible
protein stain (Pierce Biotechnology, Cramlington, North-
umberland, UK). All tissue culture products were from
Gibco (Paisley, UK) unless specified.
Cell culture
Human dermal fibroblasts both fetal (obtained from elec-
tive termination of pregnancies following local ethical
approval; gestation <14 weeks; FDF, n = 7 all digits) and
developmentally mature fibroblasts (MDF, n = 7 from
infants <2 y, digits; n = 3 from children age 4–10 y from
corrective ear surgery and n = 3 from adult from patients
undergoing elective reconstructive surgery, Breast reduc-
tions) were established by explanting tissue. No differ-
ences were seen in behaviour of cell from different body
sites. Cells were grown in Dulbecco's modified Eagle's
medium (DMEM) supplemented with 10% fetal calf
serum (FCS), 2 mM glutamine and 100 U/ml penicillin
and 100 mg/ml streptomycin (NGM) unless otherwise
specified. All experiments were performed on passage 1–6
cells. Human recombinant IGF-I and IGF-II were used at
100 ng/ml unless specified otherwise.
Cell proliferation
Fibroblasts were seeded at 5 × 103/well into a 96-microti-
tre plate (Greiner, Stonehouse, Gloucestershire, UK) and
allowed to attach overnight in minimum media (DMEM
supplemented with 0.4% FCS) to maintain cells in a
healthy but quiescent state. After, 24 hours, the media was
aspirated and replaced by test media (minimum media
with serial dilutions of IGF-I and -II) and cultured for a
further 72 hours. Cell number was assessed using WST-1
assay (Roche, Lewes, UK). Briefly 10 μl WST-1 solution
was added to each well. The cells were incubated for 1
hour in standard tissue culture conditions. The absorb-
ance, which related to the number of viable cells convert-
ing the reagent to coloured formazan crystals, was read at
450 nm on a Bio-Rad Plate reader. Experiments were per-
formed in triplicate on FDF and MDF derived cell strains
(n = 3 for each).
The WST-1 assay results were validated by using an alter-
native colourimetric assay based on the uptake of crystal
violet dye. The cells were fixed and stained with the crystal
violet/fix solution (0.5% crystal violet, 5% formol saline,
50% ethanol, 0.85% NaCl) for 10 min at room tempera-
ture and washed ×3 with PBS. The dye taken up by the
cells was then eluted using 100 μl of 33% acetic acid for
10 mins and the colour read at 540 nm on a Bio-Rad plate
reader. Wells not containing cells were used to correct for
background staining. Experiments were performed in trip-
licate on 3 cell lines for FDF and MDF (not shown). Both
methods gave identical results; however the WST-1 assay
showed considerably less variation.
Collagen synthesis
Collagen synthesis was assessed via incorporation of radi-
olabelled proline. This method allows comparison of the
effects of IGF's on synthesis of secreted collagen and de
novo protein production. Confluent fibroblast monolay-
ers were prepared in 24-well plates, cultured in pre-incu-
bation media: DMEM supplemented with 2 mM L-
proline, 50 μg/ml ascorbic acid, 2% FCS, 1 U/ml penicil-
lin/streptomycin, 2 mM L-glutamine and 7 mM Hepes.
Twenty-four hours later, the media was replaced with pre-
incubation media supplemented with 5 μCi/ml 3H L-pro-
line [2,3,4,5] (New England Nuclear, a division of Perkin
Elmer, UK) and serial dilutions of IGF-I and II (1–100 ng/
ml). After a twenty-four hour exposure period, media was
collected for analysis and total cell number per well
assessed by trypan blue exclusion using a haemocytome-
ter. All treatments were conducted in replicates of four
and the experiment repeated with each of three cell lines
(FDF and MDF respectively).
Determination of collagen and non-collagen synthesis in
culture media was evaluated in a modification of a well-
defined micro assay as previously described by Mariotti et
al [63]. Synthesis of collagen and non-collagen protein
was expressed respectively as collagenase-soluble and col-
lagenase-insoluble counts per minute (cpm). A correction
factor of 5.4 for non-collagen protein was used to adjust
for the relative abundance of proline and hydroxyproline
in collagen [64]. The resulting counts per minute for col-
lagen and non-collagenous protein production were then
normalised against viable cell number in each well and
expressed as cpm/105 cells. Relative collagen synthesis
(RCS) was calculated as the amount of collagen synthe-BMC Developmental Biology 2007, 7:124 http://www.biomedcentral.com/1471-213X/7/124
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sised as a proportion of the sum of collagen and non-col-
lagen synthesis, expressed as a percentage.
Western blotting
Fibroblasts (1 × 106 cells) were cultured in serum free
media (DMEM with 2 mM glutamine and antibiotics 100
U/ml penicillin and 1 mg/ml streptomycin; SFM) for 72
hrs. The cells were treated with either IGF-I or IGF-II for 20
mins or left in SFM (untreated control).
Cultures (1 × 106 cells) were rinsed twice with ice cold PBS
and then lysed in ice-cold buffer (50 mM Tris-HCL pH
6.8, 0.1% SDS, 1 mM phenylmethylsufonyl fluoride, 2
mM sodium orthovanadate, 1 μg/ml aprotinin). Cell
lysates were scraped using a rubber policeman from the
dishes and repeatedly pipetted to shear DNA. The lysates
were then incubated on ice for 10 mins prior to centrifu-
gation at 12,000 rpm for 10 mins to remove insoluble
material. Volumes of lysate equivalent to equal protein
were electrophoresed on a 10% sodium dodecyl sulphate-
polyacrylamide gel and transferred to a nitrocellulose
membrane using a Bio-Rad Mini Trans-Blot Cell. Mem-
branes following transfer were stained with MemCode™
reversible protein stain as per manufacturer's instructions
to ensure equivalent loading of protein. Membranes were
then blocked with Tris buffered saline containing 3%
bovine serum albumin and 0.1% polyoxyethylene-sorb-
itan monolaurate (Tween 20; Sigma, Gillingham, Dorset,
UK) for 1 hr. The membranes were washed in Tris buff-
ered saline/0.1% Tween 20 (TTBS) and then incubated
with the appropriate primary antibody for 2 hrs at room
temperature. Blots were then washed in TTBS and then
incubated in the appropriate secondary antibody conju-
gated to alkaline phosphatase for 1 hr at room tempera-
ture. The membranes were then washed and developed in
Vectar Blue Substrate (Peterborough, UK) to visualise
immunoreactive bands. All western blots were repeated in
triplicate for 5 FDF and 5 MDF cell lines.
Band density was quantified by scanning densitometry
using the UVP system. Density readings were corrected for
variations in loading, with activated (phosphorylated)
Shc being compared to total Shc, IGF-IR normalised with
β-actin and all other proteins of interest compared to the
MemCode Reversible™ (Pierce Biotechnology) protein
stain. Data presented graphically is the mean of all 5-cell
strains per tissue type.
Immunoprecipitation
Following treatment with IGF-I or IGF-II cultured quies-
cent human dermal fibroblasts (1 × 106  cells) were
washed with ice-cold PBS and then lysed in ice-cold lysis
buffer as described previously. Cell lysates were pre-
cleared by incubation with protein G-Sepharose beads at
4°C for 30 mins. The beads containing the lysates were
centrifuged and supernatants collected. Anti-Shc antibody
was added and incubated overnight at 4°C. Immunocom-
plexes were collected by centrifugation and the superna-
tants discarded. The beads with the immunocomplexes
were washed with lysis buffer, mixed with Laemmli sam-
ple buffer, boiled for 5 mins and resolved on an SDS-poly-
acrylamide gel electophoresis. Western blotting was
performed using an anti-phosphotyrosine antibody as
described earlier.
Fluorescence activated cell sorter (FACS)
Cells were placed in single cell suspension with the use of
accutase and washed with PBS. Cells (106) were incubated
with 1 μg/ml of a mouse monoclonal antibody specific for
IGF-I receptor (3B7, sc-462 Santa Cruz Biotechnology,
Inc) or an isotype control (IgG1, sc-2866 Santa Cruz Bio-
technology) for 90 min at 4°C. Cells were then washed in
PBS and incubated with fluorescein isothiocyanate-conju-
gated anti mouse for 1 hour at 4°C. Cells were then
washed again in PBS prior to FACS analysis. Data was
accumulated from 5000 cells and gated to remove debris/
cell aggregates. The intensity of fluorescence was quanti-
fied in two ways; both the mean or mode fluorescence cor-
rected for background (isotype control sample) was
calculated and compared between n = 2 each of either FDF
or MDF cell strains. All four-cell strains were stained and
analysed simultaneously to allow comparison.
Statistical analysis
Statistical significance was analysed using Student t-test
and/or ANOVA followed by all pair wise multiple com-
parison procedures (Tukey test) where appropriate. Val-
ues of p < 0.05 were considered significant. Sigma Stat 2.0
software was used for all statistical analysis.
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